• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase.

作者信息

Patel Shyam A, Bledsoe Jacob R, Higgins Anne W, Hutchinson Lloyd, Gerber Jonathan M

机构信息

Department of Medicine-Hematology/Oncology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA.

Department of Pathology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA.

出版信息

JCO Precis Oncol. 2021 Jul 9;5. doi: 10.1200/PO.21.00039. eCollection 2021 Jul.

DOI:10.1200/PO.21.00039
PMID:34409243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8367045/
Abstract
摘要

相似文献

1
Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase.博纳吐单抗诱导CD19阳性慢性髓性白血病淋巴母细胞期快速深度缓解
JCO Precis Oncol. 2021 Jul 9;5. doi: 10.1200/PO.21.00039. eCollection 2021 Jul.
2
Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia.吉妥珠单抗奥佐米星和blinatumomab 治疗慢性髓性白血病难治性混合表型急变期。
BMJ Case Rep. 2021 Nov 11;14(11):e243745. doi: 10.1136/bcr-2021-243745.
3
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.BCR-ABL酪氨酸激酶特异性抑制剂在伴有费城染色体的慢性髓性白血病急变期和急性淋巴细胞白血病中的活性
N Engl J Med. 2001 Apr 5;344(14):1038-42. doi: 10.1056/NEJM200104053441402.
4
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.FTY720，一种治疗急变期慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的新选择。
J Clin Invest. 2007 Sep;117(9):2408-21. doi: 10.1172/JCI31095.
5
Different suppression of Ph1 positive hemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML.慢性粒细胞白血病淋巴系和髓系原始细胞危象时强化化疗对Ph1阳性造血的不同抑制作用。
Haematologica. 1991 Mar-Apr;76(2):126-30.
6
Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.在经历20年“未治疗”的慢性髓性白血病后，化疗和伊马替尼诱导淋巴细胞母细胞危象出现分子缓解。
Am J Hematol. 2007 Apr;82(4):333. doi: 10.1002/ajh.20815.
7
Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.一名青少年慢性髓性白血病淋巴母细胞危象患者，在接受强化急性淋巴细胞白血病导向化疗联合持续伊马替尼治疗后，获得完全细胞遗传学缓解并实现超长生存期。
Pediatr Blood Cancer. 2016 Dec;63(12):2243-2245. doi: 10.1002/pbc.26148. Epub 2016 Jul 19.
8
T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy: a report of 14 cases.酪氨酸激酶抑制剂治疗时代慢性髓性白血病的T淋巴细胞或T/髓系母细胞期：14例报告
Int J Lab Hematol. 2017 Apr;39(2):e45-e50. doi: 10.1111/ijlh.12605. Epub 2016 Nov 13.
9
Hematopoietic stem cell involvement in positive ALL as a potential mechanism of resistance to blinatumomab therapy.造血干细胞参与阳性急性淋巴细胞白血病，作为对blinatumomab治疗耐药的一种潜在机制。
Blood. 2017 Nov 2;130(18):2027-2031. doi: 10.1182/blood-2017-05-782888. Epub 2017 Aug 21.
10
Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring.慢性期慢性髓性白血病停用酪氨酸激酶抑制剂后突发淋巴细胞母细胞危象：分子监测适度开展的警示案例
Leuk Lymphoma. 2023 Mar;64(3):746-749. doi: 10.1080/10428194.2023.2165395. Epub 2023 Jan 19.

引用本文的文献

1
Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia.与初发Ph阳性B细胞急性淋巴细胞白血病相比，处于淋巴母细胞期的慢性粒细胞白血病患者对抗CD19嵌合抗原受体T细胞疗法的反应较差。
Hemasphere. 2024 Feb 27;8(2):e49. doi: 10.1002/hem3.49. eCollection 2024 Feb.
2
Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration.病例报告：blinatumomab 治疗伴有中枢神经系统浸润的 B 细胞急性淋巴细胞白血病患者。
Front Immunol. 2023 Apr 18;14:1181620. doi: 10.3389/fimmu.2023.1181620. eCollection 2023.
3

本文引用的文献

1
Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis.接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者或诊断时其BCR-ABL1激酶结构域中的突变。
Oncol Lett. 2020 Aug;20(2):1071-1076. doi: 10.3892/ol.2020.11650. Epub 2020 May 20.
2
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
3
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations.
儿童和青少年慢性髓细胞白血病急变期的治疗：国际儿科 CML 专家小组建议。
Leukemia. 2023 Mar;37(3):505-517. doi: 10.1038/s41375-023-01822-2. Epub 2023 Jan 27.
4
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.急变期慢性髓性白血病的治疗：一种罕见且极具挑战性的疾病。
Br J Haematol. 2022 Dec;199(5):665-678. doi: 10.1111/bjh.18370. Epub 2022 Jul 22.
拿下 ALL 的“必杀技”：blinatumomab 获批 MRD 阳性 ALL。
Blood. 2019 Apr 18;133(16):1715-1719. doi: 10.1182/blood-2018-12-852376. Epub 2019 Feb 22.
4
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.Blinatumomab 治疗 B 细胞前体急性淋巴细胞白血病成人患者的微小残留病。
Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.
5
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.博纳吐单抗联合酪氨酸激酶抑制剂治疗复发的费城染色体阳性白血病的安全性和有效性
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):897-901. doi: 10.1016/j.clml.2017.08.101. Epub 2017 Aug 18.
6
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.博纳吐单抗对比化疗治疗晚期急性淋巴细胞白血病
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.
7
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.利妥昔单抗在 B 系成人急性淋巴细胞白血病中的应用。
N Engl J Med. 2016 Sep 15;375(11):1044-53. doi: 10.1056/NEJMoa1605085.
8
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.奥英妥珠单抗对比标准疗法治疗急性淋巴细胞白血病
N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.
9
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
10
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.HCVAD 联合伊马替尼或达沙替尼治疗淋巴母细胞样急变期慢性髓性白血病。
Cancer. 2014 Feb 1;120(3):373-80. doi: 10.1002/cncr.28433. Epub 2013 Oct 22.